International Agency for Research on Cancer (IARC) - Summaries & Evaluations

(Group 2B)

For definition of Groups, see Preamble Evaluation.

Supplement 7: (1987) (p. 389)

CAS No.: 60-35-5

Evidence for carcinogenicity to animals (sufficient)

Acetamide produced benign and malignant liver tumours in rats following its oral administration [ref: 1-3]. In male mice, an increased incidence of malignant lymphomas was also observed [ref: 3].

Overall evaluation

Acetamide is possibly carcinogenic to humans (Group 2B).

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Vol. 71 (1999)

Also see previous evaluation: Vol. 7 (1974)


1. IARC Monographs, 7, 197-202, 1974

2. Flaks, B., Trevan, M.T. & Flaks, A. (1983) An electron microscope study of hepatocellular changes in the rat during chronic treatment with acetamide. Parenchyma, foci and neoplasms. Carcinogenesis, 4, 1117-1125

3. Fleischman, R.W., Baker, J.R., Hagopian, M., Wade, G.G., Hayden, D.W., Smith, E.R., Weisburger, J.H. & Weisburger, E.K. (1980) Carcinogenesis bioassay of acetamide, hexanamide, adipamide, urea and p-tolylurea in mice and rats. J. environ. Pathol. Toxicol., 3, 149-170


Last updated: 13 April 1999

    See Also:
       Toxicological Abbreviations
       Acetamide (ICSC)
       ACETAMIDE (JECFA Evaluation)
       Acetamide  (IARC Summary & Evaluation, Volume 71, 1999)